Study of A3309 in Patients With Dyslipidemia

The purpose of this trial is to determine the efficacy and safety of A3309 administered to patients with dyslipidemia (high cholesterol levels).

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Dyslipidemia Dyslipidemias Lipid Metabolism Disorders Metabolic Diseases Nutritional and Metabolic Diseases

Age range

18 year–80 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

BCRC

Linköping, Sweden

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Patients meet protocol specified criteria for dyslipidemia and has successfully completed study requirements with no clinically relevant findings

Exclusion criteria

Medical history or medical condition that would not make the patient a good candidate for the study or would limit the patient´s capability to complete the study

Treatment and study plan

A3309

Drug

A3309 in two different dosage levels

Placebo

Drug

Placebo comparator once daily for the duration of the trial

Primary outcomes

Change from baseline in low-density lipoprotein (LDL) cholesterol

Time frame: eight weeks

Sponsors and collaborators

Lead sponsor

Albireo

Industry

Registry information

Official study title

A Phase IIa, Double-blind, Randomised, Placebo-controlled, Dose-finding Efficacy and Safety Study of A3309 in Patients With Dyslipidemia

Important dates

Study start: 2010
Primary completion: 2010
Study completion: 2010
First posted: Feb 17, 2010
Registry last updated: Mar 7, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed